Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

L. Baldini, L. Cro, R. Calori, L. Nobili, I. Silvestris, A. T. Maiolo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The expression of β1 (very late activation antigens, VLA 1-6) and β2 integrins (leukocyte adhesion molecules [Leu-CAM]) in cell suspensions from the peripheral blood of 70 patients with B-cell chronic lymphocytic leukemia (B-CLL), 15 patients with leukemic lymphocytic lymphoma of intermediate differentiation (IDL), as well as from the lymph nodes of 20 patients with low/intermediate-grade non-Hodgkin's lymphoma (NHL) was studied with the aim of characterizing their adhesive phenotype and evaluating its relationship to clinical behavior. CD11a (LFA-1) was more expressed in NHL and IDL than in B- CLL (P = .047), although it was demonstrable in 74.2% of cases; CD11c was more expressed in B-CLL (P <.0001), and its expression was preserved in almost all of the cases of small lymphocytic lymphoma. In NHL patients, including the cases of IDL, VLA-3 expression was observable in 8 of 35 cases (although always at a low level of intensity), while VLA-4 was almost constantly expressed in a way that was similar to its expression in control normal B cells. On the contrary, in B-CLL patients, VLA-3 was expressed (prevalently at high levels) in 87.1% of cases and VLA-4 only in 37.1%. No correlation was found between adhesion molecule patterns and the clinical features of the diseases. The biofunctional significance of the imbalance of VLA-3 and VLA-4 expression in B-CLL is not easy to explain, but it has undoubted intrinsic value as an additional marker for distinguishing B-CLL from, in particular, those B-cell neoplasms (such as IDL) that share many of the immunocyto-morphologic characteristics and the putative normal counterpart (the mantle zone) of B-CLL.

Original languageEnglish
Pages (from-to)2688-2693
Number of pages6
JournalBlood
Volume79
Issue number10
Publication statusPublished - 1992

Fingerprint

Integrin alpha4beta1
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Chemical activation
Cells
Antigens
Integrin alpha1beta1
Lymphocyte Function-Associated Antigen-1
Cell Adhesion Molecules
Integrin alpha6beta1
Integrins
Integrin alpha2beta1
B-Lymphocytes
Adhesives
Suspensions
Blood
Adhesion
Mantle-Cell Lymphoma
Molecules

ASJC Scopus subject areas

  • Hematology

Cite this

Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. / Baldini, L.; Cro, L.; Calori, R.; Nobili, L.; Silvestris, I.; Maiolo, A. T.

In: Blood, Vol. 79, No. 10, 1992, p. 2688-2693.

Research output: Contribution to journalArticle

@article{4f737220b6cf4cc08bb66daf7499b42f,
title = "Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia",
abstract = "The expression of β1 (very late activation antigens, VLA 1-6) and β2 integrins (leukocyte adhesion molecules [Leu-CAM]) in cell suspensions from the peripheral blood of 70 patients with B-cell chronic lymphocytic leukemia (B-CLL), 15 patients with leukemic lymphocytic lymphoma of intermediate differentiation (IDL), as well as from the lymph nodes of 20 patients with low/intermediate-grade non-Hodgkin's lymphoma (NHL) was studied with the aim of characterizing their adhesive phenotype and evaluating its relationship to clinical behavior. CD11a (LFA-1) was more expressed in NHL and IDL than in B- CLL (P = .047), although it was demonstrable in 74.2{\%} of cases; CD11c was more expressed in B-CLL (P <.0001), and its expression was preserved in almost all of the cases of small lymphocytic lymphoma. In NHL patients, including the cases of IDL, VLA-3 expression was observable in 8 of 35 cases (although always at a low level of intensity), while VLA-4 was almost constantly expressed in a way that was similar to its expression in control normal B cells. On the contrary, in B-CLL patients, VLA-3 was expressed (prevalently at high levels) in 87.1{\%} of cases and VLA-4 only in 37.1{\%}. No correlation was found between adhesion molecule patterns and the clinical features of the diseases. The biofunctional significance of the imbalance of VLA-3 and VLA-4 expression in B-CLL is not easy to explain, but it has undoubted intrinsic value as an additional marker for distinguishing B-CLL from, in particular, those B-cell neoplasms (such as IDL) that share many of the immunocyto-morphologic characteristics and the putative normal counterpart (the mantle zone) of B-CLL.",
author = "L. Baldini and L. Cro and R. Calori and L. Nobili and I. Silvestris and Maiolo, {A. T.}",
year = "1992",
language = "English",
volume = "79",
pages = "2688--2693",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

AU - Baldini, L.

AU - Cro, L.

AU - Calori, R.

AU - Nobili, L.

AU - Silvestris, I.

AU - Maiolo, A. T.

PY - 1992

Y1 - 1992

N2 - The expression of β1 (very late activation antigens, VLA 1-6) and β2 integrins (leukocyte adhesion molecules [Leu-CAM]) in cell suspensions from the peripheral blood of 70 patients with B-cell chronic lymphocytic leukemia (B-CLL), 15 patients with leukemic lymphocytic lymphoma of intermediate differentiation (IDL), as well as from the lymph nodes of 20 patients with low/intermediate-grade non-Hodgkin's lymphoma (NHL) was studied with the aim of characterizing their adhesive phenotype and evaluating its relationship to clinical behavior. CD11a (LFA-1) was more expressed in NHL and IDL than in B- CLL (P = .047), although it was demonstrable in 74.2% of cases; CD11c was more expressed in B-CLL (P <.0001), and its expression was preserved in almost all of the cases of small lymphocytic lymphoma. In NHL patients, including the cases of IDL, VLA-3 expression was observable in 8 of 35 cases (although always at a low level of intensity), while VLA-4 was almost constantly expressed in a way that was similar to its expression in control normal B cells. On the contrary, in B-CLL patients, VLA-3 was expressed (prevalently at high levels) in 87.1% of cases and VLA-4 only in 37.1%. No correlation was found between adhesion molecule patterns and the clinical features of the diseases. The biofunctional significance of the imbalance of VLA-3 and VLA-4 expression in B-CLL is not easy to explain, but it has undoubted intrinsic value as an additional marker for distinguishing B-CLL from, in particular, those B-cell neoplasms (such as IDL) that share many of the immunocyto-morphologic characteristics and the putative normal counterpart (the mantle zone) of B-CLL.

AB - The expression of β1 (very late activation antigens, VLA 1-6) and β2 integrins (leukocyte adhesion molecules [Leu-CAM]) in cell suspensions from the peripheral blood of 70 patients with B-cell chronic lymphocytic leukemia (B-CLL), 15 patients with leukemic lymphocytic lymphoma of intermediate differentiation (IDL), as well as from the lymph nodes of 20 patients with low/intermediate-grade non-Hodgkin's lymphoma (NHL) was studied with the aim of characterizing their adhesive phenotype and evaluating its relationship to clinical behavior. CD11a (LFA-1) was more expressed in NHL and IDL than in B- CLL (P = .047), although it was demonstrable in 74.2% of cases; CD11c was more expressed in B-CLL (P <.0001), and its expression was preserved in almost all of the cases of small lymphocytic lymphoma. In NHL patients, including the cases of IDL, VLA-3 expression was observable in 8 of 35 cases (although always at a low level of intensity), while VLA-4 was almost constantly expressed in a way that was similar to its expression in control normal B cells. On the contrary, in B-CLL patients, VLA-3 was expressed (prevalently at high levels) in 87.1% of cases and VLA-4 only in 37.1%. No correlation was found between adhesion molecule patterns and the clinical features of the diseases. The biofunctional significance of the imbalance of VLA-3 and VLA-4 expression in B-CLL is not easy to explain, but it has undoubted intrinsic value as an additional marker for distinguishing B-CLL from, in particular, those B-cell neoplasms (such as IDL) that share many of the immunocyto-morphologic characteristics and the putative normal counterpart (the mantle zone) of B-CLL.

UR - http://www.scopus.com/inward/record.url?scp=0026772281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026772281&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 2688

EP - 2693

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -